Walgreens named one of healthcare industry’s most innovative companies by Fast Company
DEERFIELD, Ill. — Fast Company has called out Walgreens as one of the world’s most innovative companies in the magazine’s "Fast 50" issue.
The publication named Walgreens one of the healthcare industry’s most innovative companies for the second time in three years, due to its leadership and healthcare services, including the chain’s Well Experience format, addressing the need for greater access to healthy foods in underserved communities, as well as plans to become the nation’s leading retail host of electric vehicle charging stations.
“We’re honored to again be recognized by Fast Company as one of the world’s most innovative organizations,” said Kermit Crawford, Walgreens president of pharmacy, health and wellness services and solutions. “With more than 7,800 community drugstores and a network of health care professionals trusted by millions of people every day, innovation is how we provide greater access to a wide variety of health and daily living needs.”
The complete list and related stories appear in the March 2012 issue of Fast Company magazine currently on newsstands and online at Fastcompany.com.
Until Walgreens and Express Scripts get an agreement I don't think that this is appropriate.
PCPAN responds to Express Scripts CEO’s comments about community pharmacists
WASHINGTON — Comments made by Express Scripts CEO George Paz after the pharmacy benefit manager’s earnings call last week has garnered some attention from a coalition that is looking to stop the merger between ESI and fellow PBM Medco Health Solutions.
During the question-and-answer portion of ESI’s fourth quarter 2011 earnings call, Paz was asked about the validation of narrow networks and providing larger savings for clients. He responded to one question by saying, "At the end of day, as I said earlier, Nexium is Nexium, Lipitor is Lipitor, drugs are drugs and it shouldn’t matter that much whose counting to 30. And I just believe that we should be able to make sure that we put the right person in front of the right cost and make sure that we serve our clients properly."
Paz also added during the Q&A that, "[We are] absolutely focused on that and we believe that the community pharmacists severe a very important role in health care, that they do a tremendous amount. But we just don’t see that one pharmacist does it that much better than another pharmacist, at least not by change. And so we’re just not going to pay those premiums."
The comments drew concerns from the Preserve Community Pharmacy Access NOW! coalition, which said Paz’s statements demonstrated the "true feelings" of the PBM and further demonstrated why the proposed merger between ESI and Medco should be stopped.
"ESI and Medco have spent the last several months trying to defend their merger against claims it would result in decreased access to local community pharmacies, but recent comments demonstrate that ESI and Medco completely devalue pharmacists and show that the claims are indeed valid," PCPAN chairwoman Eva Clayton said. "Comments like this should raise serious concerns about how a combined company with such an attitude would treat pharmacies that provide important services and employ people in our communities. This is yet another reminder that this merger must be stopped."
Click here to read the full Q&A transcript.
No comments found
FDA declines to approve Watson reproductive drug
PARSIPPANY, N.J. — The Food and Drug Administration turned down an application for a topical reproductive drug made by Watson Pharmaceuticals and Columbia Labs, the two companies said Monday.
The FDA sent the companies a complete response letter for their progesterone vaginal gel in the 8% strength. The drug is used to reduce the risk of preterm birth in women with singleton gestation and short uterine cervical length in the second trimester of pregnancy. Columbia transferred rights to the drug to Watson earlier this month, leaving Watson with full responsibility for obtaining regulatory approval.
The FDA said in the letter that results from a clinical trial of the drug did not show the levels of statistical significance that the agency requires for approval of a drug after a single late-stage clinical trial and that it would require additional clinical trial data before it could approve it.
No comments found